Document:

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT
(this “Agreement”), entered into on this April 5, 2022, is by and between IDW Media Holdings, Inc., a Delaware corporation
(the “Company”), and Howard S. Jonas (the “Employee”).

 

WHEREAS, the Employee is currently
employed as the non-executive Chairman of the Board of the Company, a non-executive officer position, and in such capacity provides strategic
guidance and other services to the Company and its subsidiaries;

 

WHEREAS, in recognition of
the Employee’s experience and abilities, the Company desires to assure itself of the continued employment of the Employee in accordance
with the terms and conditions provided herein; and

 

WHEREAS, the Employee wishes
to continue to perform services for the Company in accordance with the terms and conditions provided herein.

 

NOW, THEREFORE, in consideration
of the promises and the respective covenants and agreements of the parties herein contained, and intending to be legally bound hereby,
the parties hereto agree as follows:

 

1. Term.
This Agreement is for the period (the “Initial Term”) commencing on April 5, 2022, and terminating on April 5, 2027, or upon
the Employee’s earlier death or other termination of employment pursuant to Section 6 hereof; provided, however, that commencing
on April 5, 2027 and each anniversary thereafter, the term shall automatically be extended for one additional year beyond its otherwise
scheduled expiration unless, not later than ninety (90) days prior to any such anniversary, either party hereto shall have notified the
other party in writing that such extension shall not take effect (the Initial Term and any extensions thereof, the “Term”).

 

2. Position.
During the Term, the Employee shall serve as the non-executive Chairman of the Board of Directors of the Company (the “Board”).

 

3. Duties
and Reporting Relationship. During the Term, the Employee shall use his skills and render services to the best of his abilities on
behalf of the Company. The Employee shall dedicate as much time as is, in the judgment of the Board, necessary or advisable for the performance
his duties hereunder, it being acknowledged that the position is not a full-time position. Notwithstanding the foregoing, the Company
acknowledges that the Employee will be serving as the Chairman of the Board of IDT Corporation, Genie Energy, Ltd., and Rafael Holdings,
Inc., and as Vice Chairman of the Board of Zedge, Inc., as well as in certain other positions with business and not-for-profit entities,
and that, for so long as the Employee performs his duties hereunder, such service shall not be deemed to be a breach of the terms hereof.

 

4. Place
of Performance. The Employee shall perform his duties and conduct his business at the offices of the Company and other locations as
determined by the Employee and not reasonably objected to by the Board.

 

     

     

    

 

5. Compensation
and Related Matters.

 

(a) Base
Salary; Bonus.

 

(i) During
the Term, the Company shall pay the Employee a base salary of FOUR HUNDRED THOUSAND DOLLARS ($400,000) per annum, payable through the
issuance of restricted shares of Class B common stock, par value $0.01 per share, of the Company (“Class B Stock”), such shares
to be issued pursuant to the Company’s 2019 Stock Option and Incentive Plan (as the same may be amended, modified, restated or replaced
from time to time, the “Plan”) or other equity incentive plan adopted by the Company, subject to payment of applicable taxes
and customary withholdings.

 

Within thirty
(30) days following approval, by the stockholders of the Company of an amendment (the “Amendment”) to the Plan adding additional
shares to be available for grant thereunder (as approved by the Compensation Committee of the Board on January 13, 2022), the Company
shall issue to the Employee pursuant to the Plan (as so amended) a number of restricted shares of Class B Stock as shall have a value
(based on the closing price of the Class B Stock on the NYSE American on the trading day immediately preceding the issuance) equal to
TWO MILLION DOLLARS ($2,000,000) representing the Employee’s base salary for the entire Initial Term. Such shares shall vest in
substantially equal amount on April 5, 2023, April 5, 2024, April 5, 2025, April 5, 2026 and April 5, 2027, subject to the Employee remaining
in continuous service (as defined in the Plan) with the Company through such vesting dates. If the Amendment is not approved by the stockholders
of the Company by June 30, 2022, or if prior to issuance the Class B Stock is no longer listed on the NYSE American, the Employee and
the Company will enter into good faith discussions of alternative payment of the Employee’s base salary for the Initial Term.

 

(ii) The
Employee shall be eligible to receive bonuses as determined by the Compensation Committee of the Board.

 

(b) Business
Expenses. The Employee will be reimbursed for all ordinary and necessary business expenses incurred by him in connection with his
employment (including without limitation, expenses for travel and entertainment incurred in conducting or promoting business for the Company)
upon submission by the Employee of receipts and other documentation in accordance with the Company’s normal reimbursement procedures.

 

6. Termination.
The Employee’s employment hereunder may be terminated without breach of the Agreement only under the following circumstances:

 

(a) Death;
Disability. The Employee’s employment hereunder shall terminate upon his death or, as permitted by law, Disability. For purposes
of this Agreement, “Disability” shall mean the inability of the Employee to perform his duties on account of a physical or
mental illness for a period of one hundred twenty (120) consecutive days or one hundred eighty (180) days in any ten (10) month period,
and the term “Disabled” shall have a corresponding meaning.

 

(b) Cause.
The Company may terminate the Employee’s employment hereunder with or without “Cause.” For purposes of this Agreement,
the Company shall have “Cause” to terminate the Employee’s employment hereunder (i) upon the Employee’s conviction
for the commission of an act or acts constituting a felony under the laws of the United States or any state thereof, or (ii) upon the
Employee’s willful and continued failure to substantially perform his duties hereunder (other than any such failure resulting from
the Employee’s incapacity due to physical or mental illness), after written notice has been delivered to the Employee by the Company,
which notice specifically identifies the manner in which the Employee has not substantially performed his duties, and the Employee’s
failure to substantially perform his duties is not cured within ten (10) business days after notice of such failure has been given to
the Employee. For purposes of this Section 6(b), no act or failure to act on the Employee’s part shall be deemed “willful”
unless done or omitted to be done, by the Employee not in good faith and without reasonable belief that the Employee’s act, or failure
to act, was in the best interest of the Company.

 

    2

     

    

 

(c) Termination
by the Employee. The Employee may terminate his employment hereunder for “Good Reason” or without Good Reason. “Good
Reason” shall mean the occurrence (without the Employee’s express written consent) of any one of the following acts by the
Company, or failure by the Company to act:

 

(i) a
material breach of the Agreement by the Company;

 

(ii) the
assignment to the Employee of any duties inconsistent with the Employee’s status as an officer of the Company or a material adverse
alteration in the nature or status of the Employee’s responsibilities; or

 

(iii) any
purported termination of the Employee’s employment which is not effected pursuant to a Notice of Termination satisfying the requirement
of paragraph (d) below; for purposes of this Agreement, no such purported termination shall be effective.

 

(iv) a
material reduction in Employee’s annual Base Salary;

 

(v) relocation
of Employee’s principal place of employment to a location more than 50 miles outside of the Metropolitan New York City area; or

 

(vi) a
“Change in Control,” as defined in the Plan,

 

(each of the foregoing being a “Good Reason
Event”). Employee may terminate employment for Good Reason if (A) Employee has given written notice to the Company of the existence
of the Good Reason Event no later than ninety (90) days after its initial existence, (B) the Company has not remedied such Good Reason
Event in all material respects within thirty (30) business days after its receipt of such written notice, and (C) Employee terminated
employment within one year following the initial existence of such Good Reason Event.

 

The Employee’s right to terminate the Employee’s
employment for Good Reason shall not be affected by the Employee’s incapacity due to physical or mental illness. The Employee’s
continued employment shall not constitute consent to, or a waiver of rights with respect to any act or failure to act constituting Good
Reason hereunder. Notwithstanding the foregoing, a termination shall not be treated as a Termination for Good Reason if the Employee shall
have consented in writing to the occurrence of the event giving rise to the claim of Termination for Good Reason.

 

(d) Notice
of Termination. Any termination of the Employee’s employment by the Company or by the Employee (other than termination by reason
of the Employee’s death) shall be communicated by written Notice of Termination to the other party hereto in accordance with Section
11 hereof. For purposes of this Agreement, a “Notice of Termination” shall mean a notice that shall indicate the specific
termination provision in this Agreement relied upon and, if the termination is for “Cause,” shall set forth in reasonable
detail the facts and circumstances claimed to provide a basis for termination of the Employee’s employment under the provision so
indicated. Further, a Notice of Termination for Cause or Disability must include a copy of a resolution duly adopted by the affirmative
vote of not less than a majority of the entire membership of the Board at a meeting of the Board (after reasonable notice to the Employee
and an opportunity for the Employee, together with the Employee’s counsel, to be heard before the Board) finding that, in the good
faith opinion of the Board, the Employee was guilty of conduct set forth in the definition of Cause herein or satisfied the criteria of
a Disability, and specifying the particulars thereof.

 

    3

     

    

 

(e) Date
of Termination. “Date of Termination” shall mean if the Employee’s employment is terminated (i) by his death, the
date of his death, (ii) by reason of Disability, the date that the Employee is informed that the Board has determined him to be Disabled,
(iii) by resignation of the Employee without Good Reason, the date the Employee so notifies the Board, or (iv) pursuant to paragraph (b)
or (c) above, the date specified in the Notice of Termination; provided, however, that if within fifteen (15) business days
after any Notice of Termination is given, or if later, prior to the Date of Termination (as determined without regard to this Section
6(e)), the party receiving such Notice of Termination notifies the other party that a dispute exists concerning the termination, the Date
of Termination shall be the date on which the dispute is finally resolved, either by mutual written agreement of the parties or by a final
judgment, order or decree of a court of competent jurisdiction (which is not appealable or with respect to which the time for appeal,
therefrom has expired and no appeal has been perfected); provided further that the Date of Termination shall be extended by a notice
of dispute only if such notice is given in good faith and the party giving such notice pursues the resolution of such dispute with reasonable
diligence.

 

(f) Compensation
During Dispute. If a purported termination occurs during the Term of this Agreement, and such termination is disputed in accordance
with Section 6(e) hereof, the Company shall continue to pay the Employee the full compensation in effect when the notice giving rise to
the dispute was given (including, but not limited to, Base Salary) and continue the Employee as a participant in all compensation, benefit
and insurance plans in which the Employee was participating when the notice giving rise to the dispute was given, until the dispute is
finally resolved. Amounts paid under this Section 6(f) are in addition to all other amounts due under this Agreement and shall not be
offset against or reduce any other amounts due under this Agreement.

 

7. Compensation
Upon Termination.

 

(a) Death;
Disability. In the event that Employee’s employment is terminated pursuant to Section 6(a) hereof, then as soon as practicable
thereafter, the Company shall pay the Employee or the Employee’s Beneficiary (as defined in Section 10(b) hereof), as the case may
be, (i) all unpaid amounts, if any, to which the Employee was entitled as of the Date of Termination under Section 5 hereof and (ii) all
unpaid amounts to which the Employee was then entitled in respect of perquisites or other reimbursements (the amounts set forth in clauses
(i) and (ii) above being hereinafter referred to as the “Accrued Obligations”). In addition, in the event of the Employee’s
death, the Company shall pay Employee’s estate a lump sum payment equal to twelve (12) months of any cash portion of Employee’s
base salary (at the rate in effect on the date of his death) (the “Severance Benefit”). Any restrictions shall lapse, and
any unvested equity grants in the Company or its subsidiaries granted to the Employee in connection with his service to the Company, including,
without limitation, in respect of his base salary (“Equity Grants”) shall vest upon a termination pursuant to Section 6(a).

 

(b) Termination
for Cause; Resignation without Good Reason. If the Employee’s employment is terminated by the Company for Cause or by the Employee
other than for Good Reason, then the Company shall pay all Accrued Obligations to the Employee, and the Company shall have no further
obligations to the Employee under this Agreement.

 

    4

     

    

 

(c) Termination
Without Cause; Resignation for Good Reason. If the Company shall terminate the Employee’s employment, other than for Cause or
on the Employee’s death or Disability, or the Employee shall terminate his employment for Good Reason, then;

 

(i) the
Company shall pay to the Employee, within ten (10) days after the Date of Termination, the Accrued Obligations;

 

(ii) the
Company shall pay the Employee the Severance Benefit within sixty (60) days of the Date of Termination; and

 

(iii) any
restrictions with respect to any Equity Grants shall lapse, and any unvested Equity Grants in the Company or its subsidiaries shall vest.

 

(d) As
a condition to receiving any Severance Benefit, the Employee will be required to execute and deliver the Company’s standard release
agreement (the “Release Agreement”) within twenty-one (21) days after the Date of Termination (unless applicable law requires
a longer time period, in which case this date will be extended to the minimum time required by applicable law), and not thereafter revoke
such agreement .

 

8. Non-Disclosure.
(a) The parties hereto agree, recognize and acknowledge that during the Term the Employee shall obtain knowledge of confidential information
regarding the business and affairs of the Company. It is therefore agreed that the Employee will respect and protect the confidentiality
of all confidential information pertaining to the Company, and will not disclose in any fashion such confidential information to any person
(other than a person who is a director of, or who is employed by, the Company or any subsidiary or who is engaged to render services to
the Company or any subsidiary), without the prior written consent of the Company, (i) unless required in the course of the Employee’s
employment hereunder, or (ii) unless such disclosure is pursuant to subsection (b) below, or Employee has an independent right or obligation
to make such disclosure pursuant to applicable local, state or federal law. This Agreement does not limit Employee’s ability to
communicate with the Securities Exchange Commission or otherwise participate in any investigation or proceeding that may be conducted
by the Securities Exchange Commission, including providing documents or other information, without notice to the Company. This Agreement
further does not limit Employee’s ability to communicate with any other government agency or otherwise participate in any investigation
or proceeding that may be conducted by any government agency, including providing documents or other information, without notice to the
Company, where such limitation would be contrary to law.

 

(b) Notice of Immunity: The
Employee acknowledges that via this paragraph Company is providing the Employee with written notice that the Defend Trade Secrets Act,
18 U.S.C. § 1833(b), provides that (i) an individual shall not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law, or is
made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii) an individual
who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the employer’s trade
secret to the individual’s attorney and use such trade secret information in the court proceeding if the individual files any document
containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.

 

    5

     

    

 

9. Covenant
Not to Compete.

 

(a) Employee
hereby agrees that for a period of one (1) year following the termination of this Agreement (other than a termination of the Employee’s
employment (i) by the Employee for Good Reason or (ii) by the Company other than for Cause) (the “Restricted Period”) the
Employee shall not, directly or indirectly, whether acting individually or through any person, firm, corporation, business or any other
entity:

 

(i) engage
in, or have any interest in any person, firm, corporation, business or other entity (as an officer, director, employee, agent, stockholder,
or other security holder, creditor, consultant or otherwise) that engages in any business activity where a substantial aspect of the business
of the Company is conducted, or planned to be conducted, at any time during the Restricted Period, which business activity is the same
as, similar to or competitive with the Company as the same may be conducted from time to time;

 

(ii) interfere
with any contractual relationship that may exist from time to time of the business of the Company, including, but not limited to, any
contractual relationship with any director, officer, employee, or sales agent, or supplier of the Company; or

 

(iii) solicit,
induce or influence, or seek to induce or influence, any person who currently is, or from time to time may be, engaged or employed by
the Company (as an officer, director, employee, agent, or independent contractor) to terminate his or her employment or engagement by
the Company.

 

(b) Notwithstanding
anything to the contrary contained herein, Employee, directly or indirectly, may own publicly traded stock constituting not more than
five percent (5%) of the outstanding shares of such class of stock of any corporation covered by clause (a)(i) above if, and as long as,
Employee is not an officer, director, employee or agent of, or consultant or advisor to, or has any other relationship or agreement with
such corporation.

 

(c) Employee
acknowledges that the non-competition provisions contained in this Agreement are reasonable and necessary, in view of the nature of the
Company and his knowledge thereof, in order to protect the legitimate interests of the Company.

 

10. Successors;
Binding Agreement.

 

(a) The
Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company, by agreement in form and substance reasonably satisfactory to the Employee, to expressly
assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it
if no such succession had taken place. Failure of the Company to obtain such assumption and agreement prior to the effectiveness of any
such succession shall be a breach of this Agreement and shall entitle the Employee to compensation from the Company in the same amount
and on the same terms as he would be entitled to hereunder if he terminated his employment for Good Reason, except that for purposes of
implementing the foregoing, the date on which any such succession becomes effective shall be deemed the Date of Termination. As used in
this Agreement, “Company” shall mean the Company as defined herein defined and any successor to its business and/or assets
as aforesaid that executes and delivers the agreement provided for in this Section 10 or that otherwise becomes bound by all the terms
and provisions of this Agreement by operation of law.

 

    6

     

    

 

(b) This
Agreement and all rights of the Employee hereunder shall inure to the benefit of and be enforced by the Employee’s personal or legal
representatives, executors, administrators, successors, heirs, distributee, devisee, and legatees. If the Employee should die while any
amounts should still be payable to him hereunder if he had continued to live, all such amounts, unless otherwise provided herein, shall
be paid in accordance with the terms of this Agreement to the Employee’s devisee, legatee, or other designee or, if there be no
such designee, to the Employee’s estate (any of which is referred to herein as a “Beneficiary”).

 

11. Notice.
For purposes of this Agreement, notices, demands and all other communications provided for in this Agreement shall be in writing and shall
be deemed to have been duly given when delivered or (unless otherwise specified) mailed by United States certified or registered mail,
return receipt requested, postage paid, addressed as follows:

 

If to the Company:

IDW Media Holdings, Inc.

520 Broad Street

Newark, New Jersey 07102

Attn: Chief Executive Officer

 

If to the Employee, at the Employee’s address in the
Company’s human resources files.

 

or to such other address as either party may have furnished to the
other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.

 

12. Miscellaneous.
No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing
signed by the Employee and such other officer of the Company as may be specifically designated by the Board. No waiver by either party
hereto at any time of any breach by the other party hereto, or compliance with any condition or provision of this Agreement to be performed
by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or prior or subsequent time.
No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either
party which are not set forth expressly in this Agreement. The validity, interpretation, construction and performance of this Agreement
shall be governed by the laws of the state of New Jersey without regard to its conflicts of law principles.

 

13. Validity.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability if
any such other provision of this Agreement, which shall remain in full force and effect.

 

14. Remedies
of the Company.  Upon any termination for Cause that may cause irreparable harm to the Company or upon the violation of
the provisions of Section 8 or 9 hereof, the Company shall be entitled, if it so elects, to institute and prosecute proceedings to obtain
injunctive relief and damages, costs and expenses, including, without limitation, reasonable attorneys’ fees and expenses, with respect
to such termination.

 

15. Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together
will constitute one and the same instrument.

 

    7

     

    

 

16. Entire
Agreement. This Agreement and the other agreements referred to herein set forth the entire agreement of the parties hereto in respect
of the subject matter contained herein and, other than non-disclosure, non-compete or similar agreements, supersede any and all other
prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer,
employee or representative of any party hereto, and in prior agreements of the parties hereto in respect to the subject matter contained
herein is hereby terminated and canceled.

 

17. Special
Rules Regarding Section 409A of the Internal Revenue Code.

 

(a) It is intended that any
and all benefits under this Agreement either (i) shall not constitute “nonqualified deferred compensation” within the meaning
of Section 409A of the Internal Revenue Code (“Section 409A”), and therefore are exempt from Section 409A or (ii) are subject
to a “substantial risk of forfeiture” and exempt from Section 409A under the “short−term deferral rule”
set forth in Treasury Regulation § 1.409A−1(b)(4). In any event, all provisions of this Agreement shall be construed and interpreted
in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.

 

(b) Notwithstanding anything
herein to the contrary, if the Company determines that the Severance Benefit constitutes “nonqualified deferred compensation”
within the meaning of Section 409A, payment of such Severance Benefit shall not commence until the Employee incurs a “separation
from service” within the meaning of Treasury Regulation §1.409A−1(h) (“Separation from Service”). If, at
the time of Employee’s Separation from Service, the Employee is a “specified employee” (under Section 409A), such Severance
Benefit shall not be paid until after the earlier of (i) the expiration of the six−month period measured from the date of Employee’s
Separation from Service with the Company, or (ii) the date of the Employee’s death (the “409A Suspension Period”).

 

(c) The determination of whether
the Severance Benefit constitutes “nonqualified deferred compensation” within the meaning of Section 409A shall be made by
the Company in good faith. If the Company determines that such Severance Benefit is subject to the 409A Suspension Period, and the Employee
does not believe that such determination is reasonable, then the Company and the Employee shall mutually select, at the Company’s
expense, an independent outside counsel to render a legal opinion regarding the applicability of the 409A Suspension Period. If the outside
counsel described in the preceding sentence agrees with the Company’s determination that any items due to the Employee under this
agreement should be subject to the 409A Suspension Period, then such payment shall be made at the end of the 409A Suspension Period as
set forth in Section 17(b) hereof; provided however, if such outside counsel determines that such payment shall not be subject to the
409A Suspension Period, then such payment shall be effected within fourteen (14) days of the date of such counsel’s determination.

 

    8

     

    

 

IN WITNESS WHEREOF, the Employee
has executed this Employment Agreement, and the Company has caused this Employment Agreement to be executed by its duly authorized representative,
as of the date and year first above written.

 

	 	EMPLOYEE
	 	 	 
	 	/s/ Howard S. Jonas
	 	Howard S. Jonas
	 	 	 
	 	IDW MEDIA HOLDINGS, INC.
	 	 	 
	 	By:	/s/ Ezra Rosesaft
	 	 	Ezra Rosensaft
	 	 	Chief Executive Officer

 

 

9​

Exhibit 10.1
​
SURETY BOND BACKSTOP AGREEMENT
​
This SURETY BOND BACKSTOP AGREEMENT (this “Agreement”) is entered into as of February 14, 2021 (the “Effective Date”) by and among CytoDyn Inc., a Delaware corporation (“CytoDyn”), David Fairbank Welch, both individually and in his capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, Heidi A. Welch, both individually and in her capacity as trustee of the David F. and Heidi A. Welch Revocable Trust, and LRFA, LLC, a Delaware limited liability company (“LRFA” and, together with David F. Welch and Heidi A. Welch, each an “Indemnitor” and collectively the “Indemnitors”). CytoDyn and Indemnitors are collectively referred to herein as the “Parties” or each, individually, as a “Party”.
RECITALS
WHEREAS CytoDyn is currently (i) party to certain litigation with Amarex Clinical Research, LLC (“Amarex”) in the United States District Court for the District of Maryland, Case No. 8:2021CV02533 (the “Amarex Litigation”) and (ii) party to an arbitration proceeding with Amarex pending before the American Arbitration Association (the “Amarex Arbitration”).
WHEREAS on December 21, 2021, the Court in the Amarex Litigation issued a preliminary injunction (the “Preliminary Injunction”) requiring Amarex to supply CytoDyn with all data collected by Amarex in connection with obtaining FDA approval of certain pharmaceuticals being developed by CytoDyn, including trial master files, and authorizing CytoDyn to conduct an audit of clinical trial work provided by Amarex to CytoDyn.
WHEREAS, as a condition to conducting the audit authorized by the Preliminary Injunction, CytoDyn is required to post bond in the amount of $6,500,000 United States Dollars (the “Surety Bond”).
WHEREAS Argonaut Insurance Company, an Illinois corporation (“Surety”), has agreed that it will issue the Surety Bond subject to Indemnitors agreeing to indemnify Surety for any loss incurred by Surety in connection with the Surety Bond, as more specifically provided in that certain General Indemnity Agreement to be executed and delivered by Indemnitors to Surety in connection with the Surety Bond (the “Surety Bond Indemnity”).
WHEREAS Indemnitors are willing to enter into the Surety Bond Indemnity and backstop CytoDyn’s obligations under the Surety Bond subject to the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the foregoing recitals, the consideration set forth in this Agreement, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows.
AGREEMENT
	1.	Surety Bond Indemnity. In consideration for the Warrants (as defined below) and the Indemnification Fee (as defined below), on or before February 14, 2022, Indemnitors each agree (i) to execute and deliver to Surety the Surety Bond Indemnity in the form

​

Page 1 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

reasonably required by Surety; (ii) to identify to Surety assets of Indemnitors sufficient to support issuance of the Surety Bond; (iii) to provide to Surety such information, including financial statements, tax returns, and bank statement, requested by Surety in connection with the issuance of the Surety Bond; and (iv) to covenant with Surety that Indemnitors will not encumber, dispose of, or transfer the assets identified by Indemnitors in support of the Surety Bond Indemnity.
	2.
	Warrant Award; Reimbursement. As consideration for the obligations of Indemnitors under Section 1 of this Agreement:

		(a)
	within fourteen (14) days of issuance of the Surety Bond, CytoDyn shall issue to 4-Good Ventures LLC, a Delaware limited liability company, (A) a warrant in the form attached hereto as Exhibit 1 for the purchase of fifteen million (15,000,000) shares of CytoDyn common stock (the “Initial Warrant”), and (B) a warrant in the form attached hereto as Exhibit 2 for the purchase of fifteen million (15,000,000) shares of CytoDyn common stock (the “Make-Whole Warrant” and, together with the Initial Warrant, the “Warrants”), which Make-Whole Warrant shall be subject to exercise only if any Indemnitor makes payment to Surety of any amount under the Surety Bond Indemnity (an “Indemnity Payment”) or breaches any covenants in Section 6 of this Agreement;

		(b)
	on or before the 120th day following the date of issuance of the Warrants, CytoDyn shall use commercially reasonable efforts to file a Registration Statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) that is intended to register for resale the shares underlying the Warrants; provided, however, that in the event that CytoDyn is prevented from filing a registration statement, as a result of outstanding comments from the SEC, or because in the good faith judgment of the Board of Directors it would be materially detrimental to CytoDyn and its stockholders for such registration statement to either become effective or remain effective, because such action would (i) require premature disclosure of material information that CytoDyn has a bona fide business purpose for preserving as confidential; or (ii) render CytoDyn unable to comply with requirements under the federal securities laws, then CytoDyn shall have the right to defer taking action with respect to such S-3 filing for a period of not more than 60 days;

		(c)
	if any Indemnitor makes an Indemnity Payment, (i) such Indemnitor shall provide to CytoDyn notice in writing of such payment, detailing the amount of the Indemnity Payment, the date of the Indemnity Payment, and enclosing proof of Indemnity Payment (the “Indemnity Notice”), (ii) within 90 days of the date of the Surety Bond Indemnity, CytoDyn shall reimburse and pay such Indemnitor for all Indemnity Payments plus all unpaid and accrued interest due thereon, and (iii) commencing on the first day of each month following its receipt of an Indemnity Notice, CytoDyn shall pay such Indemnitor simple interest at the rate of 10% per annum on the outstanding balance of any Indemnity Payment that has not been repaid in full as of such date; and

​

2 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

		(d)
	if any Indemnitor pays to Surety an Indemnity Payment, in addition to the amounts owing such Indemnitor under Subsection 2(c) of this Agreement, for each Indemnity Payment, CytoDyn shall pay such Indemnitor an amount equal to the amount of the Indemnity Payment multiplied by one and a half (the “Indemnification Fee”); provided, however, the Indemnification Fee shall be deemed waived by such Indemnitor if CytoDyn has paid such Indemnitor all amounts owing under Subsection 2(c) of this Agreement on or before the date CytoDyn commences or has commenced against it a proceeding under Title 11 of the United States Code, or any liquidation, receivership, assignment for the benefit of creditors, or similar debtor relief law.

	3.
	Grant of Security Interest. To secure all amounts owing to Indemnitors under Subsections 2(c) and (d) of this Agreement, CytoDyn grants Indemnitors a security interest in the patents and patent applications referred to on Schedule 3 to this Agreement (the “Pledged Patents”). CytoDyn hereby specifically authorizes Indemnitors at any time and from time to time to file financing statements, continuation statements, and similar documents and amendments thereto required to perfect Indemnitors’ security interest in the Pledged Patents.

	4.
	Conditions to Effectiveness. The obligations of the Parties under this Agreement shall only be effective upon the occurrence of the following conditions, which may be waived by the Parties only in writing:

		(a)
	The Surety shall have issued the Surety Bond on or before February 14, 2022;

		(b)
	As of the date of the issuance of the Surety Bond, the Preliminary Injunction shall be in full force and effect and the Amarex Arbitration shall be ongoing; and

		(c)
	CytoDyn shall have obtained all required consents for the transactions contemplated by this Agreement and the pledge of the Pledged Assets.

	5.
	Representations and Warranties.

		(a)
	CytoDyn represents and warrants to Indemnitors as follows:

		(i)
	CytoDyn is duly organized and existing as a corporation under the laws of the state of Delaware. CytoDyn has the power to own its property and carry on its business as now being conducted;

		(ii)
	CytoDyn is authorized to execute, deliver, and perform this Agreement and any other instrument, document, or agreement required hereunder;

		(iii)
	This Agreement and any other documents, instruments, or agreements required pursuant to this Agreement, when executed and delivered by CytoDyn shall be the legal, valid, and binding agreement of CytoDyn and shall be enforceable against CytoDyn in accordance with the terms of such documents, instruments, or agreements; and

​

3 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

		(iv)
	CytoDyn is the owner of the Pledged Patents, free and clear of all liens, claims, interests, and licenses (other than those provided by this Agreement and other than any licenses issued pursuant to that certain Commercialization and License Agreement dated December 17, 2019, by and between Vyera Pharmaceuticals, LLC, a Delaware limited liability company, and CytoDyn (the “Vyera License”)), and Indemnitor’s security interests and liens in the Pledged Patents is first and prior to all other liens, claims, interests, and licenses in the Pledged Patents, other than the Vyera License.

		(b)
	Each Indemnitor represents and warrants to CytoDyn as follows:

		(i)
	LRFA is duly organized and existing as a limited liability company under the laws of the state of Delaware. Each Indemnitor has the power to own its property and carry on its business as now being conducted;

		(ii)
	Each Indemnitor is authorized to execute, deliver, and perform this Agreement and any other instrument, document, or agreement required hereunder;

		(iii)
	This Agreement and any other documents, instruments, or agreements required pursuant to this Agreement, when executed and delivered by Indemnitors shall be the legal, valid, and binding agreement of each Indemnitor and shall be enforceable against each Indemnitor in accordance with the terms of such documents, instruments, or agreements; and

		(iv)
	Indemnitors have sufficient unencumbered, liquid assets to enable CytoDyn to qualify for issuance of the Surety Bond.

	6.
	Covenants. CytoDyn covenants to Indemnitors as follows:

		(a)
	CytoDyn shall pay all fees and costs due or owing in connection with the issuance of the Surety Bond at or prior to its issuance.

		(b)
	Within 180 days of the issuance of the Surety Bond, CytoDyn shall post sufficient collateral to Surety in support of the Surety Bond and obtain from Surety a release of the Surety Bond Indemnity.

		(c)
	If CytoDyn is required to pay any amounts to Amarex in connection with the Amarex Litigation or the Amarex Arbitration, CytoDyn shall use commercially reasonable efforts to immediately pay or structure a settlement with Amarex such that no claim is submitted by Amarex against the Surety Bond.

​

4 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

7.General.
		(a)
	Notices. All notices and other communications provided in this Agreement shall be in writing and shall be delivered by hand or overnight courier service, or mailed by certified  or registered mail as follows:

If to CytoDyn:
CytoDyn, Inc.
Attn: Chief Financial Officer
1111 Main Street, Suite 660
Vancouver, Washington 98660
with a copy (which shall not itself constitute notice) to:
Miller Nash LLP
111 SW Fifth Ave., Suite 3400
Portland, Oregon, 97204
Attn: Mary Ann Frantz
If to Indemnitors:
David Welch
217 Camino Al Lago 
Atherton, CA 94027
		(b)
	Captions. Any captions for the sections of this Agreement are for convenience only and do not control or affect the meaning or construction of any of the provisions of this Agreement.

		(c)
	Severability. If any term, condition, or provision of this Agreement, or any other document or instrument referred to in this Agreement, is held invalid for any reason, such offending term, condition, or provision shall be stricken therefrom, and the remainder of this Agreement shall not be affected thereby.

		(d)
	Negotiated Agreement. This Agreement is a negotiated agreement. In the event of any ambiguity in this Agreement, such ambiguity shall not be subject to a rule of contract interpretation that would cause the ambiguity to be construed against any of the parties to this Agreement.

		(e)
	Entire Agreement. The only consideration for the execution of this Agreement is the consideration expressly recited herein. This Agreement and any documents referred to in this Agreement, constitute the entire agreement among CytoDyn and Indemnitors with respect to the subject matter thereof. No oral promise or agreement of any kind or nature, other than those that have been reduced to writing and set forth as described herein, has been made between CytoDyn and Indemnitors with respect to this Agreement.

​

5 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

		(f)
	Waiver of Jury Trial; Jurisdiction; Venue. THE PARTIES HEREBY IRREVOCABLY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR ANY OTHER AGREEMENT ENTERED INTO IN CONNECTION HEREWITH, OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY. EACH PARTY CONSENTS TO JURISDICTION IN ANY STATE OR FEDERAL COURT SITTING IN THE CITY OF VANCOUVER, WASHINGTON, EXCEPT WHERE THE LOCATION OF COLLATERAL MAY CAUSE JURISDICTION TO LIE IN ANOTHER FORUM. Each of the parties hereto hereby irrevocably waives any objection which it may now or hereafter have to the laying of venue of any of the aforesaid actions or proceedings arising out of or in connection with this Agreement brought in any state or federal court sitting in the City of Vancouver, Oregon and hereby further irrevocably waives and agrees not to plead or claim in any such court that any such action or proceeding brought in any such court has been brought in an inconvenient forum.

		(g)
	Applicable Law. This Agreement shall be governed by and construed under the laws of the State of Washington, without regard to principles of conflicts of law.

[SIGNATURES ON FOLLOWING PAGE]
​

6 – Surety Bond Backstop Agreement – CytoDyn – Welch

​

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date.
​
	​

	​

	​

	​

	​

	CYTODYN:
	​
	INDEMNITORS:

	​
	​
	​
	​
	​

	CytoDyn Inc., a Delaware corporation
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	By:
	/s/ Antonio Migliarese
	​
	/s/ David F. Welch

	Name:
Title:
	Antonio Migliarese
CFO & Interim President
	​
	David Fairbank Welch, both individually and in his capacity as trustee of the David F. and Heidi A. Welch Revocable Trust,

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	/s/ Heidi A. Welch

	​
	​
	​
	Heidi A. Welch, both individually and in her capacity as trustee of the David F. and Heidi A. Welch Revocable Trust

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	LRFA LLC, a Delaware limited liability company

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	By:
	/s/ David F. Welch

	​
	​
	​
	Name:
	David F. Welch

	​
	​
	​
	Title:
	President

​

7 – Surety Bond Backstop Agreement – CytoDyn – Welch

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]